The study has two main parts. The first part aims to find the right dose of ubamatamab when given alone or with cemiplimab by checking how safe it is and how the body processes the medication. The second part looks at how well these treatments work in shrinking or controlling the cancer. For patients with ovarian, fallopian tube, or primary peritoneal cancer, they must have received at least one previous treatment with platinum-based chemotherapy and have cancer that has returned or is no longer responding to treatment. For patients with endometrial cancer, they must have previously received treatment with a type of immune therapy and platinum-based chemotherapy, and their cancer must show a certain protein marker called MUC16 in at least one quarter of the tumor cells.

During the study, patients will receive their assigned treatment and be monitored regularly for side effects and to see how their cancer responds. Doctors will use scans and blood tests to check if the cancer is shrinking, staying the same, or growing. The study will also measure how the treatment affects quality of life and daily functioning through questionnaires. Blood samples will be taken to measure the amount of medication in the body and to check if the body develops any reaction to the medications. The study will continue until enough information is gathered about the safety and effectiveness of these treatments.

The purpose of the study is to evaluate how well the combination of nemvaleukin alfa and pembrolizumab works compared to chemotherapy in improving the survival of patients with this type of cancer. Participants in the study will receive either the new drug combination or chemotherapy, which may include drugs like topotecan hydrochloride, gemcitabine hydrochloride, paclitaxel, or doxorubicin hydrochloride. The treatment will be given through an intravenous infusion, which means the medication is delivered directly into the bloodstream through a vein.

Throughout the study, participants will have regular visits to monitor their health and the effects of the treatment. The study aims to gather information on overall survival, how long patients live without the cancer getting worse, and the response of the cancer to the treatment. Safety will also be closely monitored by checking for any side effects or changes in health. The study is expected to continue until 2027, providing valuable insights into the effectiveness of this new treatment approach for patients with platinum-resistant ovarian cancer.

The purpose of the study is to evaluate how these treatments affect the overall survival of patients, which means the length of time patients live after starting the treatment. Participants in the study will be randomly assigned to receive either the niraparib-dostarlimab combination or one of the chemotherapy options. The chemotherapy options may include medications such as doxorubicin hydrochloride, gemcitabine hydrochloride, bevacizumab, topotecan, or paclitaxel. These are all anti-cancer agents that work in different ways to stop the growth of cancer cells.

The study will take place over a period of up to 24 months, during which participants will receive their assigned treatment and be monitored regularly. The goal is to determine which treatment option provides the best outcomes for patients with these specific types of cancer. Participants will receive either the active treatment or a placebo, and their health will be closely observed throughout the study to ensure safety and effectiveness.

The purpose of this study is to determine if pembrolizumab, when used in combination with chemotherapy, can help patients with this type of cancer live longer without the disease getting worse. Participants in the study will receive the treatment and be monitored over a period of time to see how well the cancer responds. The study will also look at the safety of the treatment and how it affects the quality of life for those involved.

Throughout the study, participants will receive pembrolizumab through an intravenous infusion, which means the medication is given directly into a vein. The study will last for several months, and participants will have regular check-ups to monitor their health and the progress of the treatment. Some participants may receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study aims to provide valuable information on the potential benefits of pembrolizumab for patients with low-grade serous ovarian cancer.

The purpose of the study is to evaluate whether adding MK-4830 to the standard treatment of Pembrolizumab and chemotherapy can lead to a greater reduction in cancer-related DNA in the blood. Participants will receive these treatments over a period of time, with some receiving a placebo instead of MK-4830. The study will monitor changes in the levels of cancer-related DNA in the blood, as well as the overall response to the treatment, including any side effects experienced by participants.

Throughout the study, participants will undergo regular assessments to track their response to the treatment. This includes measuring changes in cancer-related DNA and evaluating the effectiveness of the treatment in reducing cancer cells. The study aims to provide valuable information on whether the addition of MK-4830 can improve outcomes for patients with these types of cancer.

The purpose of this study is to determine the best dose of these medications when used together and to evaluate how well they work in treating the cancers mentioned. The study is divided into two phases: the Dose Escalation Phase and the Dose Expansion Phase. In the Dose Escalation Phase, researchers will focus on finding the safest and most effective dose of the medications. In the Dose Expansion Phase, they will look at how well the treatment works in a larger group of patients. Participants in the study may receive either the combination of REGN5668 with Cemiplimab or REGN5668 with REGN4018.

Throughout the study, participants will receive the medications through an intravenous infusion, which means the drugs are given directly into a vein. The study will monitor the participants for any side effects and measure how the cancer responds to the treatment. The trial aims to provide valuable information on the potential benefits of these new treatment combinations for patients with these specific types of cancer.